Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Glymphatic inhibition exacerbates tau propagation in an Alzheimer’s disease model

Fig. 3

Chronic glymphatic inhibition exacerbates long-term memory impairment in a mouse model of tau propagation. Following 4 weeks of TGN-020 treatment, TGN-020 treated P301SBE injected mice do not exhibit any strong preference towards the novel unfamiliar object in the 24 h delayed trial of the Novel Object Recognition test (A). This decline in object preference is significantly greater than that observed in vehicle treated P301SBE injected mice. B TGN-020 treated animals on average appear to spend more time immobile in the open field task, with almost half of the drug treated animals spending extended periods of the time immobile. Limb clasping scores in a subset of the animals (C) indicate that TGN-020 treated P301SBE injected mice exhibit significantly greater hind-limb clasping compared to WTBE injected mice. D Representative scored example images of hind-limb clasping behaviour exhibited by animals. ▲=females, ■=males, *=p < 0.05, **=p < 0.01, n = 7–8 per group. Asterisks over bars indicate differences from baseline, asterisks over brackets indicate differences between denoted groups

Back to article page